Sierrah M. Grigsby

Sierrah M. Grigsby

Auto-generated profile, based on publicly available information

Sierrah M. Grigsby


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
TATalha Anwar
Talha Anwar
CACaroline Arellano-Garcia
Caroline Arellano-Garcia
JRJames P. Ropa
James P. Ropa
YCYu-Chih Chen
Yu-Chih Chen
HKHong Sun Kim
Hong Sun Kim
CKCelina G. Kleer
Celina G. Kleer
Overexpression of EZH2 in estrogen receptor negative (ER-) breast cancer promotes metastasis. EZH2 has been mainly studied as the catalytic component of the Polycomb Repressive Complex 2 (PRC2) that mediates gene repression by trimethylating histone H3 at lysine 27 (H3K27me3). However, how EZH2 drives metastasis despite the low H3K27me3 levels observed in ER- breast cancer is unknown. Here we show that in human invasive carcinomas and distant metastases, cytoplasmic EZH2 phosphorylated at T367 is significantly associated with ER- disease and low H3K27me3 levels. p38-mediated EZH2 phosphorylation at T367 promotes EZH2 cytoplasmic localization and potentiates EZH2 binding to vinculin and other cytoskeletal regulators of cell migration and invasion. Ectopic expression of a phospho-deficient T367A-EZH2 mutant is sufficient to inhibit EZH2 cytoplasmic expression, disrupt binding to cytoskeletal regulators, and reduce EZH2-mediated adhesion, migration, invasion, and development of spontaneous metastasis. These results point to a PRC2-independent non-canonical mechanism of EZH2 pro-metastatic function.

6 August 2018 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
LDLei Du
Lei Du
SGSierrah Grigsby
Sierrah Grigsby
AYAihong Yao
Aihong Yao
YCYujie Chang
Yujie Chang
GJGarrett Johnson
Garrett Johnson
ZNZaneta Nikolovska-Coleska
Zaneta Nikolovska-Coleska

2 January 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GGGarrett S. Gibbons
Garrett S. Gibbons
ACAmarraj Chakraborty
Amarraj Chakraborty
SGSierrah Grigsby
Sierrah Grigsby
AUAfoma C. Umeano
Afoma C. Umeano
CLChenzhong Liao
Chenzhong Liao
ZNZaneta Nikolovska-Coleska
Zaneta Nikolovska-Coleska

5 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
SGSierrah Grigsby
Sierrah Grigsby
AFAnn Friedman
Ann Friedman
JCJennifer Chase
Jennifer Chase
BWBridget Waas
Bridget Waas
JRJames Ropa
James Ropa
ZNZaneta Nikolovska-Coleska
Zaneta Nikolovska-Coleska
MLL1 (KMT2a) gene rearrangements underlie the pathogenesis of aggressive MLL-driven acute leukemia. AF9, one of the most common MLL-fusion partners, recruits the histone H3K79 methyltransferase DOT1L to MLL target genes, constitutively activating transcription of pro-leukemic targets. DOT1L has emerged as a therapeutic target in patients with MLL-driven leukemia. However, global DOT1L enzymatic inhibition may lead to off-target toxicities in non-leukemic cells that could decrease the therapeutic index of DOT1L inhibitors. To bypass this problem, we developed a novel approach targeting specific protein-protein interactions (PPIs) that mediate DOT1L recruitment to MLL target genes, and compared the effects of enzymatic and PPIs inhibition on leukemic and non-leukemic hematopoiesis. MLL-AF9 cell lines were engineered to carry mutant DOT1L constructs with a defective AF9 interaction site or lacking enzymatic activity. In cell lines expressing a DOT1L mutant with defective AF9 binding, we observed complete disruption of DOT1L recruitment to critical target genes and inhibition of leukemic cell growth. To evaluate the overall impact of DOT1L loss in non-leukemic hematopoiesis, we first assessed the impact of acute Dot1l inactivation in adult mouse bone marrow. We observed a rapid reduction in myeloid progenitor cell numbers within 7 days, followed by a loss of long-term hematopoietic stem cells. Furthermore, WT and PPI-deficient DOT1L mutants but not an enzymatically inactive DOT1L mutant were able to rescue sustained hematopoiesis. These data show that the AF9-DOT1L interaction is dispensable in non-leukemic hematopoiesis. Our findings support targeting of the MLL-AF9–DOT1L interaction as a promising therapeutic strategy that is selectively toxic to MLL-driven leukemic cells.

5 July 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AMAhmed S. A. Mady
Ahmed S. A. Mady
CLChenzhong Liao
Chenzhong Liao
NBNaval Bajwa
Naval Bajwa
KKKarson J. Kump
Karson J. Kump
FAFardokht A. Abulwerdi
Fardokht A. Abulwerdi
ZNZaneta Nikolovska-Coleska
Zaneta Nikolovska-Coleska
Protein-protein interactions (PPIs) represent important and promising therapeutic targets that are associated with the regulation of various molecular pathways, particularly in cancer. Although they were once considered “undruggable,” the recent advances in screening strategies, structure-based design, and elucidating the nature of hot spots on PPI interfaces, have led to the discovery and development of successful small-molecule inhibitors. In this report, we are describing an integrated high-throughput and computational screening approach to enable the discovery of small-molecule PPI inhibitors of the anti-apoptotic protein, Mcl-1. Applying this strategy, followed by biochemical, biophysical, and biological characterization, nineteen new chemical scaffolds were discovered and validated as Mcl-1 inhibitors. A novel series of Mcl-1 inhibitors was designed and synthesized based on the identified difuryl-triazine core scaffold and structure-activity studies were undertaken to improve the binding affinity to Mcl-1. Compounds with improved in vitro binding potency demonstrated on-target activity in cell-based studies. The obtained results demonstrate that structure-based analysis complements the experimental high-throughput screening in identifying novel PPI inhibitor scaffolds and guides follow-up medicinal chemistry efforts. Furthermore, our work provides an example that can be applied to the analysis of available screening data against numerous targets in the PubChem BioAssay Database, leading to the identification of promising lead compounds, fuelling drug discovery pipelines.

26 November 2022 in Leukemia
Verified
Journal Article
Closed access
PDF file
HHHsiangyu Hu
Hsiangyu Hu
NSNirmalya Saha
Nirmalya Saha
YYYuting Yang
Yuting Yang
Ejaz AhmadEjaz Ahmad
Ejaz Ahmad
LLLauren Lachowski
Lauren Lachowski
AMAndrew G. Muntean
Andrew G. Muntean